|Market Cap (Intraday)||492.91M|
|2yr Forward PE||N/A|
BioAtla Inc Stock, NASDAQ:BCAB
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.